Identification and quantification of DNA N6-methyladenine modification in mammals: A challenge to modern analytical technologies

Lyu, Cong; Wang, Huidong; Lai, Weiyi; Wang, Hailin

doi:10.1016/j.cbpa.2022.102259

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 129 However, research on p53‐related epigenetics is still limited and there are many gaps in our understanding of how epigenetic modification affects p53 expression. These include novel histone modifications such as histone sulfation, 130 histone lactylation, 131 and histone lysine benzoylation 132 ; novel DNA methylation modifications such as 3‐methylcytosine (3mC), 133 N4‐methylcytosine (4mC), 134 N6‐methyladenine (6mA), 135 and 7‐methylguanosine (7mG) 136 ; and mRNA modifications such as N1‐methyladenosine (m1A) and N4‐acetylcytidine (ac4C). With the rapid advancement of epigenetic sequencing technology, we can expect many breakthrough discoveries in the field of p53‐related epigenetic modification in the near future.…”

Section: The Structure Mutation and Modification Of P53mentioning

confidence: 99%

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies

Shen¹,

Wang²,

Mao³

et al. 2023

MedComm

View full text Add to dashboard Cite

Tumor suppressor p53 can transcriptionally activate downstream genes in response to stress, and then regulate the cell cycle, DNA repair, metabolism, angiogenesis, apoptosis, and other biological responses. p53 has seven functional domains and 12 splice isoforms, and different domains and subtypes play different roles. The activation and inactivation of p53 are finely regulated and are associated with phosphorylation/acetylation modification and ubiquitination modification, respectively. Abnormal activation of p53 is closely related to the occurrence and development of cancer. While targeted therapy of the p53 signaling pathway is still in its early stages and only a few drugs or treatments have entered clinical trials, the development of new drugs and ongoing clinical trials are expected to lead to the widespread use of p53 signaling‐targeted therapy in cancer treatment in the future. TRIAP1 is a novel p53 downstream inhibitor of apoptosis. TRIAP1 is the homolog of yeast mitochondrial intermembrane protein MDM35, which can play a tumor‐promoting role by blocking the mitochondria‐dependent apoptosis pathway. This work provides a systematic overview of recent basic research and clinical progress in the p53 signaling pathway and proposes that TRIAP1 is an important therapeutic target downstream of p53 signaling.

show abstract

Section: The Structure Mutation and Modification Of P53mentioning

confidence: 99%

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies

Shen¹,

Wang²,

Mao³

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…Besides cytosine methylation, other DNA modifications have been recently discovered in mammals, but their function is still under study, such as N 6 ‐methyl‐2′‐adenosine (6‐mA) or 5‐hydroxymethyluracil (5‐hmU) (Dai et al, 2021; Fu et al, 2015; Greer et al, 2015; Lyu et al, 2023; Zhang et al, 2015). These new modifications could be also potential biomarkers but first their variations need to be properly assessed.…”

Section: Introductionmentioning

confidence: 99%

Quantification of modified nucleotides and nucleosides by isotope dilution mass spectrometry

Marchante‐Gayón,

Nicolás Carcelén,

Potes Rodríguez

et al. 2023

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Epigenetic modifications are closely related to certain disorders of the organism, including the development of tumors. One of the main epigenetic modifications is the methylation of DNA cytosines, 5‐methyl‐2′‐deoxycycytidine. Furthermore, 5‐mdC can be oxidized to form three new modifications, 5‐(hydroxymethyl)‐2′‐deoxycytidine, 5‐formyl‐2′‐deoxycytidine, and 5‐carboxy‐2′‐deoxycytidine. The coupling of liquid chromatography with tandem mass spectrometry has been widely used for the total determination of methylated DNA cytosines in samples of biological and clinical interest. These methods are based on the measurement of the free compounds (e.g., urine) or after complete hydrolysis of the DNA (e.g., tissues) followed by a preconcentration, derivatization, and/or clean‐up step. This review highlights the main advances in the quantification of modified nucleotides and nucleosides by isotope dilution using isotopically labeled analogs combined with liquid or gas chromatography coupled to mass spectrometry reported in the last 20 years. The different possible sources of labeled compounds are indicated. Special emphasis has been placed on the different types of chromatography commonly used (reverse phase and hydrophilic interaction liquid chromatography) and the derivatization methods developed to enhance chromatographic resolution and ionization efficiency. We have also revised the application of bidimensional chromatography and indicated significant biological and clinical applications of these determinations.

show abstract

Quantitative analysis of N6-methyladenine at single-base resolution in mitochondrial DNA of hepatocellular carcinoma by deaminase-mediated sequencing

Shao,

Wu,

et al. 2024

Chinese Chemical Letters

View full text Add to dashboard Cite

Identification and quantification of DNA N6-methyladenine modification in mammals: A challenge to modern analytical technologies

Cited by 4 publications

References 31 publications

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies

Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies

Quantification of modified nucleotides and nucleosides by isotope dilution mass spectrometry

Quantitative analysis of N6-methyladenine at single-base resolution in mitochondrial DNA of hepatocellular carcinoma by deaminase-mediated sequencing

Contact Info

Product

Resources

About